Physician profile
Gerardo Neri
NPI 1255686234
$1,713.77
in general payments reported to CMS, 2019-2025
32 companies · $588 in 2025
The $588 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $312 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.20 | 2021-2025 | |
| Novo Nordisk INC | $185.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.12 | 2021-2022 | |
| Cala Health, INC. | $102.14 | 2025 | Cala Kiq |
| Pfizer INC. | $95.02 | 2021-2025 | |
| Lilly USA, LLC | $87.06 | 2021 | |
| Amgen INC. | $53.64 | 2021-2022 | |
| Axsome Therapeutics, INC. | $48.69 | 2025 | Symbravo |
| Medtronic, INC. | $48.49 | 2021 | |
| Csl Behring | $46.64 | 2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $43.28 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $42.79 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $38.76 | 2025 | Tascenso Odt, Bafiertam |
| Nestle Healthcare Nutrition INC. | $34.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.26 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.25 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $26.41 | 2025 | |
| Tanabe Pharma America, INC. | $26.30 | 2025 | Radicava |
| Biohaven Pharmaceutical Holding Company LTD. | $25.77 | 2022 | |
| Optinose US, INC. | $23.23 | 2021 | |
| Hologic Sales and Service, LLC | $22.68 | 2022 | |
| Ucb, INC. | $22.43 | 2025 | Fintepla |
| Neurocrine Biosciences, INC. | $22.27 | 2025 | |
| Astellas Pharma US INC | $21.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.50 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $20.28 | 2022 | |
| Abbott Laboratories | $19.36 | 2025 | Infinity |
| Glaxosmithkline, LLC. | $18.46 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2022 | |
| Kaleo, INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Neri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.